Psilocybin and Psychedelic Therapy: Adverse Effects and Patient Safety

Andrew T. Austin · 11 October 2026

Safety is an active part of psychedelic therapy. It begins with deciding who should receive treatment, continues through supervision of the acute experience and extends into the weeks afterwards. A reassuring room and a supportive practitioner matter, but they cannot remove every pharmacological or psychological risk. The quality of care becomes especially clear when someone fails to improve, becomes frightened or develops symptoms that persist.

Psilocybin-assisted treatment has often been tolerated within carefully selected clinical populations. Common adverse effects are usually temporary. Serious reactions and prolonged difficulties have nevertheless occurred. These observations need to be considered together: a treatment can be promising, often manageable and still require substantial safety measures. Neither enthusiasm nor alarm provides a substitute for a precise account of the possible harms.

On this page

• Expected effects, adverse effects and serious events
• The common acute adverse effects
• Cardiovascular effects and medical vulnerability
• Psychosis, mania and changes in reality testing
• Persistent perceptual and psychological difficulties
• Medicines, withdrawal and combined exposures
• Suicidal thinking and deterioration after treatment
• Consent, boundaries and professional conduct
• Why risk estimates remain incomplete

Expected effects, adverse effects and serious events

Changes in perception, emotion and the sense of self are expected pharmacological effects of psilocybin. Whether an effect is also adverse depends partly on its intensity, duration and consequences. A transient visual alteration that the person finds interesting differs clinically from persistent visual disturbance that interferes with reading or driving. An anticipated effect can still become harmful.

The terms severe and serious also describe different things. Severe usually refers to intensity. Serious is a formal safety category concerned with outcomes such as a threat to life, hospitalisation, significant disability or another medically important event. Intense anxiety can be severe without meeting the criteria for a serious event. Conversely, an event requiring hospital care should not disappear from the safety account because the person later interprets it positively.¹

An adverse event occurs during or after treatment without necessarily being caused by it. An adverse reaction carries an assessment of a causal relationship. That distinction matters in depression, where symptoms and risk can fluctuate independently of a new intervention. Uncertainty about causation should be stated clearly, alongside a description of what happened and what care was required.

The common acute adverse effects

Headache, nausea, anxiety, dizziness and increased blood pressure occur more often with therapeutic psilocybin than with comparison treatments in pooled randomised data. These are clinically relevant effects even when they settle within the short observation period. Frequency varies with the patient group, dose, comparator and how actively symptoms are sought.²

A person may experience strong fear, confusion or the feeling that ordinary control has been lost. The accompanying bodily sensations can make that fear more convincing. Calm support and an organised environment can reduce avoidable escalation, but the treating team must also consider medical causes when symptoms are unusual or severe. Psychological interpretation should follow an appropriate assessment, rather than replace it.³

The expression “a bad trip” has limited clinical precision. It can compress very different events into a phrase: a difficult but contained experience, a panic reaction, dangerous behaviour, a medical complication or a lasting psychological problem. Describing the actual symptoms is more useful. How long did they last? Was the person oriented and able to cooperate? What intervention was needed? What happened afterwards?

The immediate environment should support physical safety as well as emotional comfort. Impaired judgement, altered depth perception and dizziness can affect movement. A clinical programme needs suitable supervision, access to appropriate assessment and a plan for escalation. These are practical consequences of administering a medicine that alters consciousness.

Cardiovascular effects and medical vulnerability

Classic psychedelics can temporarily increase blood pressure and heart rate. Selected, medically screened participants may tolerate these changes, but that observation cannot resolve the risk for someone with significant cardiovascular disease. Baseline blood pressure, symptoms, relevant history and interacting medicines need attention. A treatment setting must be able to recognise when a physiological response has become clinically concerning.⁴

Repeated exposure raises a separate question. Some serotonergic drugs can affect heart valves through particular receptor mechanisms. The relevance of this concern to sustained psychedelic microdosing remains uncertain; it is not an established incidence of valve disease caused by psilocybin. This uncertainty means that long-term safety cannot be inferred from a handful of supervised sessions; it does not establish harm from every pattern of repeated use.⁴

Limited information is also a clinical fact. If pregnant people, older adults with substantial medical illness or people taking complex medication combinations were excluded from a programme, the absence of harm in that programme provides little direct reassurance for them. The appropriate response is to recognise the missing evidence. It is not to assume that an apparently natural substance must be benign in an unstudied situation.³

Psychosis, mania and changes in reality testing

During an acute psychedelic state, unusual perceptions and beliefs may occur. Persistent loss of reality testing after the expected drug effects have subsided requires a different level of concern. Clinically relevant features can include fixed implausible beliefs, marked disorganisation, distressing hallucinations and an inability to manage ordinary safety. The context and duration help distinguish a transient drug effect from an emerging psychiatric disorder.

Mania has its own pattern: markedly increased energy or irritability, reduced need for sleep, accelerated thought and behaviour that may become impulsive or dangerous. Feeling better after depression is not, by itself, mania. The concern is a sustained change in activation, judgement and functioning. A history suggestive of bipolar illness therefore matters before treatment, as do significant changes in sleep afterwards.⁵

Most modern clinical programmes have excluded people with psychotic disorders and other relevant vulnerabilities. Reviews of psychedelic-associated psychosis include heterogeneous populations and studies of uneven quality. Their estimates cannot be converted into a precise personal risk for someone excluded from contemporary trials. The evidence supports neither a claim that psychosis is inevitable nor an assurance that screening makes it impossible.⁶

If symptoms suggest mania or psychosis, clinical assessment should take priority over an interpretation about awakening, spiritual emergence or necessary transformation. A person may later choose a particular framework for understanding what happened. That choice should remain compatible with timely care for impaired sleep, judgement or safety.

Persistent perceptual and psychological difficulties

Some people describe continuing anxiety, derealisation, depersonalisation or an unsettling change in their sense of self after a psychedelic experience. Derealisation concerns a feeling that the world is unreal or strangely distant; depersonalisation concerns detachment from one’s own experience. These descriptions do not establish a diagnosis on their own. They do identify symptoms that deserve to be heard and assessed.

Accounts from people recruited because they had persistent negative experiences show that prolonged difficulties can occur. Such samples are useful for describing the nature of distress. They cannot establish what proportion of all users will develop it, because people without problems were not recruited in a comparable way.⁷

Hallucinogen persisting perception disorder involves recurrent or persistent perceptual symptoms after the acute drug state, associated with clinically significant distress or impairment and requiring exclusion of other explanations. Visual symptoms can also arise from migraine, eye disease, neurological conditions, anxiety and other medicines or substances. A diagnosis of HPPD requires an appropriate clinical assessment; a brief online description is insufficient.⁸

Persistent harm is also relevant to supervised treatment: the 2026 EPISODE trial reported a serious adverse reaction involving HPPD. That observation refutes an absolute assurance of no such risk in clinical care, while providing insufficient information for a stable incidence estimate.⁹

The response should be proportionate and specific. What is the symptom? When did it begin? Is it improving, stable or worsening? How does it affect sleep, work and relationships? Reassurance can be helpful when grounded in assessment. Repeatedly telling a distressed person that the experience must be beneficial can instead make it harder for them to seek appropriate help.

Medicines, withdrawal and combined exposures

Interaction risk depends on the actual compounds involved. Psilocybin, MDMA, ketamine and an ayahuasca preparation have different pharmacology. A reassuring finding about one combination cannot establish the safety of another. The word “psychedelic” is too broad to function as a prescribing instruction.¹⁰

Psychiatric medicines may change the intensity of psychedelic effects, and some combinations create additional safety concerns. The available interaction literature includes small controlled studies alongside case reports and less controlled observations. It leaves substantial gaps for people taking several medicines. Assessment therefore requires a complete account of prescribed drugs, over-the-counter products, supplements and other substance use.¹⁰

There are two separate decisions: whether concurrent use is appropriate, and whether changing an established medicine is appropriate. Stopping an antidepressant can cause withdrawal and may destabilise an illness that it was partly controlling. A protocol that required participants to discontinue a medicine does not establish a generally safe timetable for other patients. Changes need to be individualised with the prescriber.¹¹

A muted subjective response is not a reliable sign that taking more is safe. Neither should a person change medication to create a more intense experience. The relevant clinical objective is a favourable balance of benefit and harm. Intensity is an effect of treatment, not an independent medical goal.

Suicidal thinking and deterioration after treatment

Depression can carry a risk of suicide before any psychedelic treatment is considered. Suicidal thoughts, suicidal behaviour and self-injury have also been reported during follow-up in depression trials. Establishing the contribution of the drug, the illness, treatment changes or other circumstances can be difficult. Care must respond to the event while that uncertainty remains.¹²

A patient may experience disappointment after a highly anticipated treatment, especially if others described it as life-changing. Promises that could make nonresponse feel like a personal failure should be avoided. Treatment should include a plan for continuing care, a named point of contact and a clear route to urgent assessment. It should also allow the patient to describe ambivalence, anger or worsening symptoms without being regarded as obstructive.

Consent, boundaries and professional conduct

Altered consciousness can increase dependence on the people providing care. The patient may become unusually trusting, emotionally exposed or uncertain about how to challenge an interpretation. This vulnerability requires particularly clear professional boundaries. The practitioner’s confidence, charisma or personal psychedelic history does not remove the need for accountability.

Consent should address foreseeable discomfort, uncertain benefit, possible deterioration, the arrangements for physical contact and how concerns can be raised. A general agreement to treatment is not permission for any intervention a practitioner later considers meaningful. Sexualised contact or exploitation has no therapeutic justification. Boundaries should be established while the person can consider them carefully.¹³

The same restraint applies to interpretation. A vivid image is not proof of a historical event. A feeling of extraordinary certainty is not a dependable measure of truth. Suggestions about recovered memories, family relationships or spiritual identity can have consequences long after the session. Support should preserve the person’s capacity to reflect and question a practitioner’s explanation.¹⁴

There should be a route for reporting difficulties outside the immediate therapeutic relationship. A person who feels harmed may be reluctant to challenge someone on whom they depended during an intense experience. Clinical governance should make disagreement and complaint possible without threatening access to follow-up.

Why risk estimates remain incomplete

Rare outcomes require large numbers of adequately followed patients to estimate reliably. Selection can make a treatment look safer than it would be in a broader population. Short follow-up can miss delayed problems. Passive questioning can miss symptoms that a patient is embarrassed to mention or does not recognise as relevant.

A 2025 assessment of psilocybin trials found substantial variation in the quality of adverse-effect reporting. It did not find evidence of systematic underreporting in publications compared with trial registries. The useful conclusion is that monitoring and reporting need greater consistency, not that all favourable findings must have concealed harm.¹⁵

Safety assessment should include what happened after discharge, who stopped attending, what additional treatment became necessary and whether symptoms affected daily life. The patient’s interpretation should be recorded alongside clinical observations. Neither account should automatically erase the other.

Responsible psychedelic care must be able to accommodate the person who benefits and the person who is harmed. That requires measured expectations before treatment, competent supervision during it and accessible care afterwards. A trustworthy service recognises adverse outcomes plainly and responds with appropriate care.

References

1. International Council for Harmonisation. E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1995; European Medicines Agency guideline record.
2. Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e245960. doi:10.1001/jamanetworkopen.2024.5960.
3. Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.
4. Nahlawi A, Ptaszek LM, Ruskin JN. Cardiovascular effects and safety of classic psychedelics. Nat Cardiovasc Res. 2025;4:131–144. doi:10.1038/s44161-025-00608-2.
5. National Institute for Health and Care Excellence. Bipolar disorder in adults (QS95): Referral for specialist mental health assessment. Quality statement 1; accessed 11 October 2026.
6. Sabé M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30:1223-1255. doi:10.1038/s41380-024-02800-5.
7. Bremler R, Katati N, Shergill P, et al. Case analysis of long-term negative psychological responses to psychedelics. Sci Rep. 2023;13:15998. doi:10.1038/s41598-023-41145-x.
8. Martinotti G, et al. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci. 2018;8:47. doi:10.3390/brainsci8030047.
9. Mertens LJ, Koslowski M, Betzler F, et al. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. JAMA Psychiatry. 2026;83:448–460. doi:10.1001/jamapsychiatry.2026.0132.
10. Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.
11. National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Recommendations; accessed 11 October 2026.
12. Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81:1225–1235. doi:10.1001/jamapsychiatry.2024.2546.
13. Guss J, Krause R, Sloshower J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (Using Acceptance and Commitment Therapy as a Therapeutic Frame). 2020. Research therapy manual; author-deposited preprint. doi:10.31234/osf.io/u6v9y.
14. McGovern HT, Grimmer HJ, Doss MK, et al. An Integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024;2:69. doi:10.1038/s44271-024-00120-6.
15. Marinis J, Clarke ST, Guerin AA, et al. Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review. BJPsych Open. 2025;11:e261. doi:10.1192/bjo.2025.10847.

General medical information. Decisions about treatment, medication changes and persistent symptoms require an individual assessment by an appropriately qualified clinician.